In a paper featured on the cover of the October issue of ACS Nano, the research team outlines their results, which represent a proof-of-concept demonstration for establishing the new method to perform bioassays that are typically conducted to measure the effects of a substance on a living organism and are essential in the development of new drugs. The paper is available online http://pubs.acs.org/doi/full/10.1021/nn101908e .
“We envision that our new approach can be adopted for generating nanoparticle-based vehicles to deliver a variety of cargos, including different genes, siRNA, proteins, drugs, as well as any combination of these elements,” said Professor Hsian-Rong Tseng, an associate professor of molecular and medical pharmacology and member of CNSI and Crump.
“Unlike the conventional methods based manual operations, the UCLA microchip is specifically designed to avoid human error, accelerate handling procedures, enhance reproducibility and achieve economical use of samples,” said Dr. Hao Wang, a staff research associate in Dr. Tseng’s research laboratory and the lead author of this paper. “It allows automated formulation of a large-scale library consisting of up to 648 different DNA-containing nanoparticles within 2.5 hours.”
Over the past six years, Tseng’s research group has pioneered the exploration of digital microfluidics for sequential and parallel chemical reactions. Digital microfludics is an alternative technology for lab-on-a-chip systems based upon micromanipulation of isolated droplets.
The research team is currently exploring the use of these highly efficient nano-vehicles for delivery of genes that facilitate the reprogramming of human cells in order to generate induced pluripotent stem cells (iPSCs) which are crucial in the field of regenerative medicine.
Led by professor Tseng, the UCLA team collaborated with researchers from the Center for Nanoscience and Nanotechnology at Wuhan Textile University, China and the University of Texas Health Center in Houston, Texas.
The research was supported by NIH-NCI NanoSystems Biology Cancer Center and California Institute of Regenerative Medicine.
The California NanoSystems Institute at UCLA is an integrated research facility located at UCLA and UC Santa Barbara. Its mission is to foster interdisciplinary collaborations in nanoscience and nanotechnology; to train a new generation of scientists, educators and technology leaders; to generate partnerships with industry; and to contribute to the economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California. An additional $850 million of support has come from federal research grants and industry funding. CNSI members are drawn from UCLA’s College of Letters and Science, the David Geffen School of Medicine, the School of Dentistry, the School of Public Health and the Henry Samueli School of Engineering and Applied Science. They are engaged in measuring, modifying and manipulating atoms and molecules — the building blocks of our world. Their work is carried out in an integrated laboratory environment. This dynamic research setting has enhanced understanding of phenomena at the nanoscale and promises to produce important discoveries in health, energy, the environment and information technology.